Mankind Pharma Cash flow Statement
Figures in Cr
Consolidated Cash Flow Results
Mar'25
Mar'24
Mar'23
Mar'22
Mar'21
Mar'20
No of Months
12
12
12
12
12
12
Profit Before Tax
2,524.00
2,399.00
1,671.00
1,974.00
1,691.00
1,437.00
Adjustment
601.00
212.00
298.00
30.00
-5.00
108.00
Changes In working Capital
-146.00
-17.00
166.00
-586.00
-94.00
-145.00
Cash Flow after changes in Working Capital
2,980.00
2,593.00
2,136.00
1,419.00
1,591.00
1,400.00
Cash Flow from Operating Activities
2,413.00
2,152.00
1,813.00
919.00
1,137.00
1,069.00
Cash Flow from Investing Activities
-12,624.00
-2,080.00
-1,051.00
-1,368.00
-1,221.00
-435.00
Cash Flow from Financing Activities
10,232.00
5.00
-739.00
604.00
-7.00
-530.00
Net Cash Inflow / Outflow
21.00
77.00
21.00
155.00
-92.00
103.00
Opening Cash & Cash Equivalents
382.00
304.00
283.00
127.00
219.00
116.00
Cash & Cash Equivalent on Amalgamation / Take over / Merger
0.00
0.00
0.00
0.00
0.00
0.00
Cash & Cash Equivalent of Subsidiaries under liquidations
0.00
0.00
0.00
0.00
0.00
0.00
Translation adjustment on reserves / op cash balances foreign subsidiaries
0.00
0.00
0.00
0.00
0.00
0.00
Effect of Foreign Exchange Fluctuations
0.00
0.00
0.00
0.00
0.00
0.00
Closing Cash & Cash Equivalent
403.00
382.00
304.00
283.00
127.00
219.00
Figures in INR Cr
Seasonal companies are compared with the same quarter last year
Seasonal companies are compared with the same quarter last year
Compare Cash Flow Results of Mankind Pharma
Figures in Cr
consolidated Cash Flow Results
Change(INR)
Change(%)
Profit Before Tax
2524.78
6026.7
-3,502.00
-58.11%
Adjustment
601.77
1020.4
-419.00
-41.03%
Changes In working Capital
-146.42
1531.5
-1,677.00
-109.56%
Cash Flow after changes in Working Capital
2980.13
8578.6
-5,598.00
-65.26%
Cash Flow from Operating Activities
2413.38
6776.7
-4,363.00
-64.39%
Cash Flow from Investing Activities
-12624.07
-8377.1
-4,247.00
-50.70%
Cash Flow from Financing Activities
10232.56
2014.2
8,218.00
408.02%
Net Cash Inflow / Outflow
21.87
413.8
-392.00
-94.71%
Opening Cash & Cash Equivalents
382.01
413
-31.00
-7.50%
Cash & Cash Equivalent on Amalgamation / Take over / Merger
0
0
0.00
0.00%
Cash & Cash Equivalent of Subsidiaries under liquidations
0
0
0.00
0.00%
Translation adjustment on reserves / op cash balances foreign subsidiaries
0
0
0.00
0.00%
Effect of Foreign Exchange Fluctuations
0
0
0.00
0.00%
Closing Cash & Cash Equivalent
403.88
826.8
-423.00
-51.15%
Cash Flow - Snapshot (Consolidated) - Mar'25
YoY Growth in year ended Mar 2025 is 12.12% vs 18.70% in Mar 2024
Mar'25
Mar'24
Change(%)
Cash Flow from Operating Activities
2,413.38
2,152.44
12.12%






